SUGARNSALT Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Breakthrough T1D and the Canadian Institutes of Health Research. The goal of this study is to determine whether a medication called sotagliflozin (SOTA) can help slow the progression of kidney function decline in people with type 1 diabetes. SOTA is a drug in the family of medications called SGLT1 and SGLT2 inhibitors and is currently FDA-approved to reduce the risk of being admitted to the hospital due to heart failure. Some studies have shown that drugs like SOTA may also slow the progression of kidney disease in people with and without diabetes.

The total time that you will be in this study is about 3 years and 4 months. You will be compensated for your participation in the study for a total of $900 once you complete all study visits.

Key Eligibility Criteria:

• Are 18 years or older
• Diagnosed with type 1 diabetes for at least 8 years & continuously treated with insulin
• Have been told by your doctor that you have diabetic kidney disease or protein in your urine

If you are interested or would like more information, please contact the study team at 971-610-3005 or email sugarnsalt@ohsu.edu.

OHSU IRB# 27158

AB-CDE Type 1 Diabetes Study

We are pleased to announce the launch of the Development and Evaluation of App-Based Certified Diabetes Education (AB-CDE) Therapy for People Living with T1D using MDI study early January of 2026. This 38-week clinical research study aims to evaluate how advanced technology, and personalized support can help people with type 1 diabetes improve their glucose control.

Participants will use several innovative tools, including the Dexcom G6 continuous glucose monitor (CGM), an insulin dose capture system (Tempo pens and Tempo button), and the DailyDose app, which provides tailored insulin dosing recommendations. Each participant will also receive an iPhone and Apple Watch to collect data on sleep and physical activity. After a two-week run-in period, participants will be randomized into either a control group or an intervention group.

Those in the intervention group will receive training to use the full DailyDose system, which provides personalized insulin dosing recommendations based on glucose, insulin, meal, and exercise data phase whereas control group will continues standard data logging which involves use of the Dexcom G6 CGM, the insulin dose capture system (Tempo pens and Tempo button), and the Data-logging Mode of DailyDose for the entire study. The AB-CDE Study aims to demonstrate how digital tools and behavioral support can empower individuals with type 1 diabetes to achieve better long-term health outcomes.

Key Eligibility Criteria:

• Type 1 Diabetes for at least 1 year
• Age 18 and older
• HbA1c 7.5–11.5%
• On multiple insulin injection therapy

If you are interested in participating in this trial, please contact OHSU study staff (Samrita Thapa or Matthew Howard) by phone or email:

Samrita Thapa: 503-494-8421
Matthew Howard: 503-418-2209
Email: oregonapc@ohsu.edu

OHSU IRB# 25791

TINSAL-FISH Trial

The OHSU Harold Schnitzer Diabetes Center (PI: Dr. Rodica Busui, MD PhD) is part of a multicenter trial funded by the National Institute of Health to identify new therapies that could reverse diabetic neuropathy, a very common and challenging complication of diabetes that leads to nerve damage and loss. The trial is evaluating whether fish oil, alone and in combination with salsalate, a drug approved to treat arthritis may be effective to treat diabetic peripheral neuropathy, and identify new targets that could be tested in a future trial. This study is being conducted at the University of Iowa, at the University of Michigan, and Oregon Health and Sciences University (OHSU).

You will be compensated for your participation in the study for a total of $300 once you complete all study visits.

Key Eligibility Criteria:

• Are 18 years or older
• Have type 2 diabetes
• Have an HbA1c at screening less than 9.5%

Duration: About 6 months.

If you are interested or would like more information, please contact the study team at 971-484-5758 or 971-610-3005 or email tinsalfish@ohsu.edu.

OHSU IRB# 27479

PRECIDENTD Trial

The OHSU Harold Schnitzer Diabetes Center, under the leadership of Dr. Rodica Busui, MD, PhD, is participating in this multicenter clinical trial funded by Patient-Centered Outcomes Research Institute (PCORI). The goal of this study is to learn more about the only two classes of diabetes medications (GLP-1 & SGLT2i) shown to reduce the risk of heart and kidney disease for people with type 2 diabetes, since people with type 2 diabetes are twice as likely to have heart disease or suffer a stroke compared to someone who does not have diabetes. Both mediation classes are effective in reducing the risk of heart or kidney disease in people with type 2 diabetes, however, the study aims to understand which medication class is better suited to different populations within type 2 diabetes.

The total time that you will be in this study is about 4 years. For each year that you participate in the study and complete each year’s visits, you will be compensated $500 annually through 2029.

Key Eligibility Criteria:

• Diagnosed with type 2 diabetes
• Age 40 years or older where:
  • Over age 40 and have had a heart attack, stroke, or stents to open their blood vessels
  • Over age 60 with an Hb1c >8, or who smoke

If you are interested or would like more information, please contact the study team at 971-509-4222 or email precidentd@ohsu.edu.

OHSU IRB# 28069